UK Markets closed
  • FTSE 100

    7,519.17
    +31.02 (+0.41%)
     
  • FTSE 250

    20,294.79
    +382.39 (+1.92%)
     
  • AIM

    920.51
    +5.76 (+0.63%)
     
  • GBP/EUR

    1.1848
    +0.0028 (+0.24%)
     
  • GBP/USD

    1.2242
    +0.0165 (+1.37%)
     
  • BTC-GBP

    19,603.67
    +626.64 (+3.30%)
     
  • CMC Crypto 200

    565.00
    +33.78 (+6.36%)
     
  • S&P 500

    4,202.42
    +79.95 (+1.94%)
     
  • DOW

    33,276.58
    +502.17 (+1.53%)
     
  • CRUDE OIL

    89.93
    -0.57 (-0.63%)
     
  • GOLD FUTURES

    1,813.80
    +1.50 (+0.08%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    19,610.84
    -392.60 (-1.96%)
     
  • DAX

    13,711.89
    +176.92 (+1.31%)
     
  • CAC 40

    6,536.03
    +46.03 (+0.71%)
     

Lonza's first-half core EBITDA gains 16.5%

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: Logo of Swiss pharmaceutical group Lonza is seen in Basel
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies.

First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs.

For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

The company is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins as well as cell and gene therapies. Under the plan, Lonza earlier this month announced a 500 million franc investment in Switzerland to fill biotech drugs into vials.

The company, which is a key supplier of vaccine maker Moderna, is banking on long-term growth in the biopharmaceuticals sector well beyond the pandemic.

(Reporting by Ludwig Burger, Editing by Miranda Murray)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting